Prevention of sudden cardiac death - Lessons from recent controlled trials

Circulation Journal

Volumn 69, Issue 6, 2005, Pages 625-629

  Richter, Sergio ^a   Duray, Gabor ^a   Grönefeld, Gerian ^a   Israel, Carsten W ^a   Hohnloser, Stefan H ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Coronary artery disease; Implantable cardioverter defibrillator; Randomized controlled trials; Sudden cardiac death

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; STATINE DERIVATIVE;

CAUSE OF DEATH; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DRUG EFFICACY; HEART VENTRICLE TACHYCARDIA; HIGH RISK POPULATION; HUMAN; META ANALYSIS; MORTALITY; PRIMARY PREVENTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SUDDEN DEATH; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CORONARY ARTERIOSCLEROSIS; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TACHYCARDIA, VENTRICULAR;

EID: 20444396631     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.625     Document Type: Review

References (30)

1. Weaver WD, Hill D, Fahrenbruch CE, Copass MK, Martin JS, Cobb LA, et al. Use of automatic external defibrillator in the management of out-of-hospital cardiac arrest. N Engl J Med 1988; 319: 661-666.
2. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report of the effects of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
3. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12.
4. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-674.
5. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675-682.
6. Camm JA, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, et al. Mortality in patients after a recent myocardial infarction: A randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004; 109: 990-996.
7. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-497.
8. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 1999; 353: 2001-2007.
9. CIBIS-II investigators and Committee. The Cardiac Insufficiency Bisoprolol study II (CIBIC II): A randomised trial. Lancet 1999; 353: 9-13.
10. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
11. McMurray J, Kober L, Robertson M, Dargie H, Colucci W, Lopez-Sendon J, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: Results of the carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45: 525-530.
12. The Heart Outcomes Prevention Evaluation Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
13. Domanski MJ, Exner DV, Borkow CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33: 598-604.
14. Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure and left ventricular dysfunction. Circulation 2004; 110: 1413-1417.
15. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
16. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
17. De Sutter J, Tavernier R, De Buyzere M, Jordaens L, De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000; 36: 773-775.
18. Chiu JH, Abdelhadi RH, Chung MK, Gurm HS, Marrouche NF, Saliba WI, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 2005; 95: 490-491.
19. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. N Engl J Med 1996; 335: 1933-1940.
20. Bigger JT for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997; 337: 1569-1575.
21. Buxton AE, Lee KL, Fischer JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999; 341: 1882-1890.
22. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
23. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Randomized trial of prophylactic implantable cardioverter defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-2488.
24. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, de Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.
25. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.
26. Wilber DJ, Zareba W, Hall WJ, Brown MW, Lin AC, Andrews ML, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004; 109: 1082-1084.
27. Dorian P, Connolly S, Hohnloser SH. Why don't ICDs decrease all-cause mortality after MI? Insights from the DINAMIT study (abstract). Circulation 2004; 110(Suppl III): III-502.
28. Grönefeld G, Thorpe KE, Connolly SJ, Dorian P, Fin E, Hohnloser SH. Competing risks for arrhythmic versus non-arrhythmic death in prophylactic ICD therapy early after myocardial infarction (abstract). Circulation 2004; 110(Suppl III): III-502.
29. Gillis AM. Prophylactic implantable cardioverter-defibrillators after myocardial infarction: Not for everyone. N Engl J Med 2004; 351: 2540-2542.
30. Kadish A. Prophylacic defibrillator implantation: Toward an evidence-based approach. N Engl J Med 2005; 352: 285-287.